Amy T Page1, Rhonda M Clifford1, Kathleen Potter1, Darren Schwartz1,2, Christopher D Etherton-Beer1,3. 1. School of Medicine and Pharmacology, University of Western Australia, 35 Stirling Highway, Crawley, 6009, Western Australia, Australia. 2. Graylands Hospital, Mt Claremont, Western Australia, Australia. 3. Royal Perth Hospital, Perth, Western Australia, Australia.
Abstract
AIMS: Deprescribing is a suggested intervention to reverse the potential iatrogenic harms of inappropriate polypharmacy. The review aimed to determine whether or not deprescribing is a safe, effective and feasible intervention to modify mortality and health outcomes in older adults. METHODS: Specified databases were searched from inception to February 2015. Two researchers independently screened all retrieved articles for inclusion, assessed study quality and extracted data. Data were pooled using RevMan v5.3. Eligible studies included those where older adults had at least one medication deprescribed. The primary outcome was mortality. Secondary outcomes were adverse drug withdrawal events, psychological and physical health outcomes, quality of life, and medication usage (e.g. successful deprescribing, number of medications prescribed, potentially inappropriate medication use). RESULTS: A total of 132 papers met the inclusion criteria, which included 34 143 participants aged 73.8 ± 5.4 years. In nonrandomized studies, deprescribing polypharmacy was shown to significantly decrease mortality (OR 0.32, 95% CI: 0.17-0.60). However, this was not statistically significant in the randomized studies (OR 0.82, 95% CI 0.61-1.11). Subgroup analysis revealed patient-specific interventions to deprescribe demonstrated a significant reduction in mortality (OR 0.62, 95% CI 0.43-0.88). However, generalized educational programmes did not change mortality (OR 1.21, 95% CI 0.86-1.69). CONCLUSIONS: Although nonrandomized data suggested that deprescribing reduces mortality, deprescribing was not shown to alter mortality in randomized studies. Mortality was significantly reduced when applying patient-specific interventions to deprescribe in randomized studies.
AIMS: Deprescribing is a suggested intervention to reverse the potential iatrogenic harms of inappropriate polypharmacy. The review aimed to determine whether or not deprescribing is a safe, effective and feasible intervention to modify mortality and health outcomes in older adults. METHODS: Specified databases were searched from inception to February 2015. Two researchers independently screened all retrieved articles for inclusion, assessed study quality and extracted data. Data were pooled using RevMan v5.3. Eligible studies included those where older adults had at least one medication deprescribed. The primary outcome was mortality. Secondary outcomes were adverse drug withdrawal events, psychological and physical health outcomes, quality of life, and medication usage (e.g. successful deprescribing, number of medications prescribed, potentially inappropriate medication use). RESULTS: A total of 132 papers met the inclusion criteria, which included 34 143 participants aged 73.8 ± 5.4 years. In nonrandomized studies, deprescribing polypharmacy was shown to significantly decrease mortality (OR 0.32, 95% CI: 0.17-0.60). However, this was not statistically significant in the randomized studies (OR 0.82, 95% CI 0.61-1.11). Subgroup analysis revealed patient-specific interventions to deprescribe demonstrated a significant reduction in mortality (OR 0.62, 95% CI 0.43-0.88). However, generalized educational programmes did not change mortality (OR 1.21, 95% CI 0.86-1.69). CONCLUSIONS: Although nonrandomized data suggested that deprescribing reduces mortality, deprescribing was not shown to alter mortality in randomized studies. Mortality was significantly reduced when applying patient-specific interventions to deprescribe in randomized studies.
Authors: M A Espeland; P K Whelton; J B Kostis; J L Bahnson; W H Ettinger; J A Cutler; L J Appel; S Kumanyika; D Farmer; J Elam; A C Wilson; W B Applegate Journal: Arch Fam Med Date: 1999 May-Jun
Authors: Sion Scott; Allan Clark; Carol Farrow; Helen May; Martyn Patel; Michael James Twigg; David John Wright; Debi Bhattacharya Journal: Int J Clin Pharm Date: 2018-06-20
Authors: Sashika Samaranayaka; Robert J Walker; Ari Samaranayaka; Sarah Derrett; John W B Schollum Journal: Drugs Aging Date: 2018-11 Impact factor: 3.923
Authors: Ashok Krishnaswami; Michael A Steinman; Parag Goyal; Andrew R Zullo; Timothy S Anderson; Kim K Birtcher; Sarah J Goodlin; Mathew S Maurer; Karen P Alexander; Michael W Rich; Jennifer Tjia Journal: J Am Coll Cardiol Date: 2019-05-28 Impact factor: 24.094
Authors: Jean-Baptiste Beuscart; Lisa G Pont; Stefanie Thevelin; Benoit Boland; Olivia Dalleur; Anne W S Rutjes; Johanna I Westbrook; Anne Spinewine Journal: Br J Clin Pharmacol Date: 2017-01-18 Impact factor: 4.335
Authors: José Alberto Domínguez-Alonso; David Conde-Estévez; David Bosch; Maria Pi-Figueras; Ignacio Tusquets Journal: Clin Transl Oncol Date: 2020-05-24 Impact factor: 3.405